Company news

AnGes. Inc. news in 2026

AnGes. Inc.'s news releases, calls and decks from 2026, newest first.

View company

AnGes.: Consolidated Financial Report for the Second Quarter 2026

August 14, 2026

Notice Regarding the Conduct of a Type B CMC Meeting for the HGF gene therapy product

May 14, 2026

Financial Results Summary of 1st Quarter 2026

May 8, 2026

AnGes.: Consolidated Financial Report for the First Quarter 2026

May 8, 2026

COLLATEGENE® (HGF gene therapy product); Proprietary ＆ USAN Names

April 29, 2026

Announcement of Publication of a Paper on Secondary Screening for Mucopolysaccharidoses Using Dried Blood Spots

April 2, 2026

Notice of First Patient Dosed in an Investigator-Initiated Clinical Trial Aimed at Preventing Brain Injury in Hemodialysis Patients Using the Jointly Developed Tie2 Receptor Agonist (AV-001)

March 24, 2026

Notice Regarding the Publication of the Research Article on Our HGF Gene Therapy Product in Circulation

March 10, 2026

Vasomune Therapeutics, Inc., and AnGes, Inc., Announce US FDA Clearance of Investigational New Drug (IND) Application For Pegevongitide (AV-001) Treatment in Resuscitation of Severely Burned Patients

March 4, 2026

Notice of the 27th annual general meeting of shareholders

March 2, 2026

Notice Regarding Partial Changes to the Use of Proceeds from the Issuance of the 46th Stock Acquisition Rights

February 24, 2026

Notice Regarding Execution of an Unsecured Private Placement Bond Facility (Revolving Type) Total Amount Purchase Agreement and Issuance of the 2nd Unsecured Corporate Bonds (Private Placement)

February 24, 2026

Introduction of the Policy Regarding Actions to Address Large-Scale Purchases of the Company’s Shares, etc. (Takeover Response Policy)

February 16, 2026

AnGes.: Consolidated Financial Report for the Fiscal Year 2025

February 10, 2026

Notice Regarding the Type “B” Clinical Meeting for HGF Gene Therapy Product

January 6, 2026

Decks in 2026